News
SRPT
19.40
-2.78%
-0.56
Sarepta Therapeutics: Pipeline Binary Risks and Elevidys Uptake Uncertainty Support Neutral Rating Through 2026
TipRanks · 23h ago
Weekly Report: what happened at SRPT last week (0504-0508)?
Weekly Report · 1d ago
Sarepta Broadens Beyond Elevidys With siRNA Progress And FDA Milestones
Simply Wall St · 2d ago
Is Sarepta Therapeutics (SRPT) A Potential Opportunity After Sharp Multi‑Year Share Price Declines?
Simply Wall St · 3d ago
Trump plans to fire FDA commissioner Marty Makary, WSJ reports
TipRanks · 3d ago
Sarepta Therapeutics (SRPT) Gets a Buy from Wedbush
TipRanks · 3d ago
A Look At Sarepta Therapeutics (SRPT) Valuation After Its First Quarter Profit Turnaround
Simply Wall St · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise
Reuters · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Albemarle, Howmet, Travere Therapeutics
Reuters · 4d ago
IBD: Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?
Dow Jones · 4d ago
SAREPTA THERAPEUTICS SHARES DOWN 3.3% AFTER LOWER Q1 SALES FOR GENE THERAPY
Reuters · 4d ago
H.C. Wainwright Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)
TipRanks · 4d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: RxSight (RXST), Sight Sciences (SGHT) and Sarepta Therapeutics (SRPT)
TipRanks · 4d ago
Sarepta Therapeutics (SRPT) Gets a Buy from Oppenheimer
TipRanks · 4d ago
Sarepta Therapeutics: Hold Rating Reaffirmed as Strong Elevidys Sales Offset by Pipeline and Execution Uncertainties
TipRanks · 4d ago
Gil Blum Reiterates Sell on Sarepta as Elevidys Momentum Slows and Regulatory Risks Mount
TipRanks · 4d ago
Sarepta Therapeutics (SRPT) Gets a Hold from RBC Capital
TipRanks · 4d ago
BUZZ-Sarepta falls on lower quarterly sales for gene therapy
Reuters · 4d ago
Wells Fargo Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)
TipRanks · 4d ago
SAREPTA THERAPEUTICS INC <SRPT.O>: LEERINK PARTNERS RAISES TARGET PRICE TO $20 FROM $15
Reuters · 5d ago
More
Webull provides a variety of real-time SRPT stock news. You can receive the latest news about Sarepta Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.